svmpharma real world evidence - drive better decision making and gain real world insights with...
TRANSCRIPT
For more on RWE visit: www.svmpharma.com
1. Real World Evidence opportunities in the NHS
2. RWE in submissions to NICE grew 6% in 2016. RWE has found it’s place, but what next?
3. Key to Market Access: Making the most out of Real World Evidence
RWE messages that you may have missed out on(Click on the links below to find out more)
Drive better decision making and gain Real World Insights with healthcare professional engagement
CONTACT US [email protected]
+44(0) 1252 417030SVMPharma Limited
www.svmpharma.com
SVMPharma RWE projects are built on the strengths of:• Knowing the RWE landscape• Establishing connections with
healthcare professionals and key opinion leaders
• Intelligent use of technology
To read the article, continue onto the next page
CONTACT US [email protected]
+44(0) 1252 417030SVMPharma Limited
www.svmpharma.com
Drive better decision making and gain Real World Insights with healthcare professional engagement
RWE data collection is a differentexperience to conventional clinical trials,and allows much greater freedom forengaging with the healthcare professionals(HCPs) and the centres taking part.
From the moment the project iscommissioned, all sites are engagedthrough a Steering Group approach. TheSteering Group consists of Key OpinionLeaders such as site lead investigators whoare supportive of the study and able toshare clinical data from their site. Thegroup also includes other keycommissioning stakeholders. Together, thegroup is consulted as to the design of theproject and their extensive experience isused to determine what data are available,where the data are available, and whatdata are. They provide insight into how thedata collection should be undertaken toensure the data are fit for purpose,strategic support and define the studyobjectives and assumptions.
The objective of the Steering Group is toensure the most pertinent collection
parameters are chosen based on extensiveinput, validation and guidance from HCPsand ensures that the data can be reliablycollected without encountering large datagaps. This feasibility step is key in outliningand ensuring comprehensive datacollection fit for the model to be used forHTA submission. Encouraging the HCPs totake an active part in the project has anumber of benefits:1. It establishes and grows the
relationship with prescribing centresand key opinion leaders
2. Adding expertise and experience tothe project aids with problem solving
3. Lead HCPs may be involved incongress abstracts, posterpresentation, and resulting journalpublications, adding weight to theproject and its findings
Real World Evidence studies offer greater opportunity to engage with Key Opinion Leadersand Healthcare Professionals. Unlike clinical trials, HCP input can be involved in thedecision-making and planning, and is in fact highly useful and encouraged. Involving thoseclosest to the patients in your study will mean a higher quality output and greaterunderstanding of real world clinical practice.
“It was a seamless, effortless process …generating meaningful and clinicallyrelevant results that can be applied toimprove our practice.”
- HCP specialist in the disease area on one of SVMPharma’s recent projects
CONTACT SVMPHARMA
Vaneet NayarDirector SVMPharma
Tel: +44 (0) 1252 417030
SVMPharma Ltd
Visit svmpharma.com
Follow @svmpharma
Follow on Google+
Connect via LinkedIn
Get In Touch